Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
EXEL 
Exelixis Inc (EXEL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: EXEL (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
20 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $44.74
1 Year Target Price $44.74
| 7 | Strong Buy |
| 4 | Buy |
| 9 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 38.68% | Avg. Invested days 49 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 10.07B USD | Price to earnings Ratio 17.99 | 1Y Target Price 44.74 |
Price to earnings Ratio 17.99 | 1Y Target Price 44.74 | ||
Volume (30-day avg) 20 | Beta 0.29 | 52 Weeks Range 25.12 - 49.62 | Updated Date 08/29/2025 |
52 Weeks Range 25.12 - 49.62 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.08 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 27.01% | Operating Margin (TTM) 37.58% |
Management Effectiveness
Return on Assets (TTM) 17.24% | Return on Equity (TTM) 29% |
Valuation
Trailing PE 17.99 | Forward PE 17.54 | Enterprise Value 9591519545 | Price to Sales(TTM) 4.52 |
Enterprise Value 9591519545 | Price to Sales(TTM) 4.52 | ||
Enterprise Value to Revenue 4.3 | Enterprise Value to EBITDA 12.27 | Shares Outstanding 269203008 | Shares Floating 231837211 |
Shares Outstanding 269203008 | Shares Floating 231837211 | ||
Percent Insiders 2.23 | Percent Institutions 96.84 |
Upturn AI SWOT
Exelixis Inc
Company Overview
History and Background
Exelixis, Inc. was founded in 1994 and is a biotechnology company focusing on discovering, developing, and commercializing new medicines to treat cancers. The company has evolved from a genomics-based drug discovery firm to a fully integrated biopharmaceutical company with a portfolio of approved products and a pipeline of potential new therapies.
Core Business Areas
- Oncology: Exelixis is primarily focused on developing and commercializing therapies for various types of cancer. This includes research, development, and commercialization activities.
Leadership and Structure
Exelixis is led by Vicki L. Goodman, M.D., as the Executive Vice President, Product Development & Medical Affairs, and Peter Lamb, Ph.D., as the Executive Vice President and Chief Scientific Officer. The company operates with a functional organizational structure that allows cross departmental co-ordination for efficiency and effectiveness.
Top Products and Market Share
Key Offerings
- CABOMETYXu00ae (cabozantinib): CABOMETYX is a tyrosine kinase inhibitor (TKI) approved for advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and differentiated thyroid cancer (DTC). While specific market share data fluctuates, CABOMETYX holds a significant share in the RCC market, competing with drugs like sunitinib, pazopanib, and others. CABOMETYX's global net product revenue in 2023 was approximately $1.4 billion. Competitors include Pfizer (Sutent), Novartis (Votrient), and Bristol Myers Squibb (Opdivo).
- COMETRIQu00ae (cabozantinib): COMETRIQ is used to treat progressive metastatic medullary thyroid cancer (MTC). The drug is available under the name CABOMETYX for other indications. Market share is smaller compared to CABOMETYX due to the rarity of MTC. Sanofi and AstraZeneca have competitors in this market.
Market Dynamics
Industry Overview
The oncology market is characterized by high growth driven by an aging population, increasing cancer incidence, and advancements in targeted therapies and immunotherapies. There is strong competition between pharmaceutical companies. The market is subject to stringent regulatory requirements and pricing pressures.
Positioning
Exelixis is positioned as a key player in the TKI space, particularly in RCC and HCC. Its competitive advantages include the established efficacy and safety profile of cabozantinib, along with a strong commercial infrastructure. The company focuses on developing and commercializing differentiated therapies.
Total Addressable Market (TAM)
The global oncology market is projected to reach over $500 billion by 2030. Exelixis is positioned to capture a significant portion of this TAM through its established products and pipeline of new therapies. Exelixis's TAM is tied specifically to the types of cancers their products and pipeline target, which are smaller segments of the total oncology market.
Upturn SWOT Analysis
Strengths
- Established presence in RCC and HCC
- Strong commercial infrastructure
- Proven efficacy and safety of cabozantinib
- Experienced management team
- Strong financial position with a robust balance sheet
Weaknesses
- Reliance on cabozantinib for revenue
- Exposure to generic competition
- Pipeline depends on successful trials
- High R&D expenses
- Sensitivity to regulatory changes
Opportunities
- Expansion into new indications for cabozantinib
- Development of new therapies through internal R&D
- Strategic partnerships and acquisitions
- Growth in emerging markets
- Advancements in precision medicine and targeted therapies
Threats
- Competition from other pharmaceutical companies
- Pricing pressures from payers
- Patent expirations
- Clinical trial failures
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- PFE
- NVS
- BMY
- MRK
- AZN
Competitive Landscape
Exelixis competes with major pharmaceutical companies in the oncology market. The company's advantages include the established efficacy of CABOMETYX and focus on developing new therapies. Disadvantages include dependence on cabozantinib and the competitive landscape.
Growth Trajectory and Initiatives
Historical Growth: Exelixis has experienced significant revenue growth driven by the success of CABOMETYX. The company's financial performance has improved substantially over the past decade as the company matured.
Future Projections: Analysts project continued revenue growth for Exelixis driven by CABOMETYX and potential new therapies. Growth rates are expected to moderate as the product matures.
Recent Initiatives: Recent initiatives include expanding the indications for cabozantinib, advancing the pipeline of new therapies, and exploring strategic partnerships and acquisitions.
Summary
Exelixis demonstrates good financial health and market positioning within oncology, particularly with CABOMETYX. Its dependence on this single drug represents a risk. Exelixis is focused on expanding the drug indications and developing new therapies. The company needs to remain vigilant against competitors and pricing pressures to sustain growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Exelixis Investor Relations
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Company Press Releases
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary depending on the source. Financial data is based on publicly available information and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Exelixis Inc
Exchange NASDAQ | Headquaters Alameda, CA, United States | ||
IPO Launch date 2000-04-07 | CEO, President & Director Dr. Michael M. Morrissey Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1147 | Website https://www.exelixis.com |
Full time employees 1147 | Website https://www.exelixis.com | ||
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an ADC consisting of a MMAE payload conjugated to a human mAb targeting the tumor antigen 5T4; and XL495, a small molecule inhibitor of PKMYT1. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent Pharma Solutions, Inc.; Iconic Therapeutics, Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.